Currently, there are 34.90M common shares owned by the public and among those 30.57M shares have been available to trade.
The company’s stock has a 5-day price change of 97.44% and -1.14% over the past three months. RAPT shares are trading -93.00% year to date (YTD), with the 12-month market performance down to -92.23% lower. It has a 12-month low price of $0.79 and touched a high of $27.35 over the same period. RAPT has an average intraday trading volume of 556.14K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 62.36%, 14.56%, and -52.80% respectively.
Institutional ownership of RAPT Therapeutics Inc (NASDAQ: RAPT) shares accounts for 75.05% of the company’s 34.90M shares outstanding.
It has a market capitalization of $62.14M and a beta (3y monthly) value of 0.12. The earnings-per-share (ttm) stands at -$2.78. Price movements for the stock have been influenced by the stock’s volatility, which stands at 19.28% over the week and 12.09% over the month.
Earnings per share for the fiscal year are expected to increase by 19.56%, and 43.38% over the next financial year.
Looking at the support for the RAPT, a number of firms have released research notes about the stock. Stifel stated their Hold rating for the stock in a research note on November 13, 2024, with the firm’s price target at $7-$2. Piper Sandler coverage for the RAPT Therapeutics Inc (RAPT) stock in a research note released on November 11, 2024 offered a Neutral rating with a price target of $2. Guggenheim on their part issued Neutral rating on May 10, 2024.
